Business
Fortress Biotech, Inc.: As a result, our product candidates may never be successfully developed or commercialized.
Revenue increased 9.7% to $63.3M, while Net income increased 114.8% to $6.8M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $63.3MOK
- Profitability — Net income $6.8MOK
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — dividends paid were $664.0KNote
Where the revenue comes from
Fiscal 2025, as Fortress Biotech, Inc. reports it. History and quarterly detail are in the app.
- Journey$61.9M
- Avenue Therapeutics Inc$1.4M
Leadership changes
From Fortress Biotech, Inc.'s own filings, the day they're filed.
- Lucy Lu · Directors · departureeff. 2025-04-15
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Fortress Biotech, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.